PE20120637A1 - 5-alquinil-piridinas - Google Patents

5-alquinil-piridinas

Info

Publication number
PE20120637A1
PE20120637A1 PE2011001817A PE2011001817A PE20120637A1 PE 20120637 A1 PE20120637 A1 PE 20120637A1 PE 2011001817 A PE2011001817 A PE 2011001817A PE 2011001817 A PE2011001817 A PE 2011001817A PE 20120637 A1 PE20120637 A1 PE 20120637A1
Authority
PE
Peru
Prior art keywords
alkinyl
pyridines
compounds
cycloalkyl
alkyl
Prior art date
Application number
PE2011001817A
Other languages
English (en)
Inventor
Tobias Wunberg
Siegfried Schneider
Der Veen Lars Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40719954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20120637A1 publication Critical patent/PE20120637A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 5-ALQUINIL-PIRIDINAS DE FORMULA (1) DONDE R1 JUNTO CON LA PIRIDINA FORMA UN ANILLO HETEROARILO DE 9 A 10 MIENBROS O R1 Y R4 SON CADA UNO Ra, Rb, ENTRE OTROS, DONDE Ra ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C10), ENTRE OTROS; Rb ES =O, -OCF3, -OCN, -NO2, ENTRE OTROS; R2 Y R3 SON CADA UNO ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ARILO(C6-C10), HETEROARILO DE 5 A 12 MIEMBROS; m ES DE 0 A 2; n ES DE 0 A 3. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PI3-QUINASAS SIENDO UTILES EN EL TRATAMIENTO DE SARCOMA DE KAPOSI, GLOMERULONEFRITIS, ASTROCITOMA FIBRILAR, CARCINOMA DE COLON
PE2011001817A 2009-04-21 2010-04-21 5-alquinil-piridinas PE20120637A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09158327 2009-04-21

Publications (1)

Publication Number Publication Date
PE20120637A1 true PE20120637A1 (es) 2012-05-26

Family

ID=40719954

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001817A PE20120637A1 (es) 2009-04-21 2010-04-21 5-alquinil-piridinas

Country Status (23)

Country Link
US (2) US20110098275A1 (es)
EP (1) EP2421846B1 (es)
JP (1) JP5635592B2 (es)
KR (1) KR20120004529A (es)
CN (1) CN102459224A (es)
AP (1) AP2011005894A0 (es)
AR (1) AR076332A1 (es)
AU (1) AU2010240963A1 (es)
BR (1) BRPI1013716A2 (es)
CA (1) CA2759368A1 (es)
CL (1) CL2011002625A1 (es)
CO (1) CO6460762A2 (es)
EA (1) EA201101517A1 (es)
EC (1) ECSP11011454A (es)
IL (1) IL215161A0 (es)
MA (1) MA33222B1 (es)
MX (1) MX2011011021A (es)
PE (1) PE20120637A1 (es)
SG (1) SG175272A1 (es)
TN (1) TN2011000531A1 (es)
TW (1) TW201103905A (es)
UY (1) UY32565A (es)
WO (1) WO2010122069A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
PL2411393T3 (pl) 2009-03-23 2014-06-30 Glenmark Pharmaceuticals Sa Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
WO2013177092A1 (en) * 2012-05-23 2013-11-28 Sunshine Lake Pharma Co., Ltd. Substituted alkynyl pyridine compounds and methods of use
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
CA3158951A1 (en) 2016-08-15 2018-02-22 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
UA85087C2 (en) * 2004-04-23 2008-12-25 Бристол-Майэрс Сквибб Компани Monocyclic heterocycles as kinase inhibitors
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
US20100048543A1 (en) 2005-02-01 2010-02-25 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
EP2099757B1 (en) * 2006-11-16 2014-06-25 Allergan, Inc. Sulfoximines as kinase inhibitors
HUE029837T2 (en) * 2008-07-29 2017-04-28 Boehringer Ingelheim Int 5-alkynyl pyrimidines
US20110230472A1 (en) 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity

Also Published As

Publication number Publication date
ECSP11011454A (es) 2011-12-30
EP2421846A1 (en) 2012-02-29
AP2011005894A0 (en) 2011-10-31
IL215161A0 (en) 2011-12-29
SG175272A1 (en) 2011-11-28
CA2759368A1 (en) 2010-10-28
JP2012524750A (ja) 2012-10-18
EA201101517A1 (ru) 2012-05-30
TN2011000531A1 (en) 2013-05-24
US9090564B2 (en) 2015-07-28
KR20120004529A (ko) 2012-01-12
UY32565A (es) 2010-11-30
CN102459224A (zh) 2012-05-16
AR076332A1 (es) 2011-06-01
CO6460762A2 (es) 2012-06-15
JP5635592B2 (ja) 2014-12-03
MA33222B1 (fr) 2012-04-02
EP2421846B1 (en) 2016-01-06
MX2011011021A (es) 2011-11-02
US20110098275A1 (en) 2011-04-28
US20130196975A1 (en) 2013-08-01
BRPI1013716A2 (pt) 2016-04-05
WO2010122069A1 (en) 2010-10-28
TW201103905A (en) 2011-02-01
AU2010240963A1 (en) 2011-10-13
CL2011002625A1 (es) 2012-04-20

Similar Documents

Publication Publication Date Title
ES2515194T3 (es) Derivados de pirrolidina
PE20110196A1 (es) 5-alquinil-pirimidinas
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
PE20120637A1 (es) 5-alquinil-piridinas
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
PE20131343A1 (es) Derivados de acido benzoico
SV2016005328A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
AR098912A1 (es) Inhibidores de syk
PE20110819A1 (es) Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
AR077765A1 (es) Inhibidores de los virus flaviviridae
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
PE20121358A1 (es) Derivados de indol como inhibidores itk
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR084277A1 (es) Compuestos utiles para el tratamiento del sida
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
PE20090775A1 (es) Nuevos derivados de biarilo
PE20130155A1 (es) Derivados de ariletinilo
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2

Legal Events

Date Code Title Description
FD Application declared void or lapsed